Jacobio Pharmaceuticals Co., Ltd.
12
5
5
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 12 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
Role: lead
A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration
Role: lead
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
Role: lead
JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation
Role: lead
A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors
Role: lead
A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors
Role: lead
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
Role: lead
JAB-BX102 Monotherapy and Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors
Role: lead
A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors
Role: lead
A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors
Role: lead
A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China
Role: lead
JAB-3068 Activity in Adult Patients With Advanced Solid Tumors
Role: lead
All 12 trials loaded